Trial Developments: AstraZeneca reported mixed clinical trial outcomes recently, with a setback in its breast cancer study offset by strong results in lung cancer treatments that cut progression risks significantly. Observers on social media noted the data's potential to bolster the company's oncology portfolio amid ongoing market scrutiny.
Analyst Shifts: Deutsche Bank revised its stance on the stock to Hold from Sell, citing the latest trial insights and raising its price target slightly. Discussions highlighted how such moves reflect broader investor reassessment following the announcements.
Additional Activity: Partnership updates involving quantum computing for drug development and an insider share purchase drew attention as signs of internal confidence. Social media sentiment around these elements remains mixed overall.
Note: This discussion summary was generated from an AI condensation of post data.
AstraZeneca Insider Trading Activity
AstraZeneca insiders have traded $AZN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AZN stock by insiders over the last 6 months:
- MANI SHARMA (See Remarks) purchased 20 shares for an estimated $3,248
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AstraZeneca Congressional Stock Trading
Members of Congress have traded $AZN stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AZN stock by members of Congress over the last 6 months:
- SENATOR ALAN ARMSTRONG has traded it 2 times. They made 2 purchases worth up to $65,000 on 03/31, 03/30 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
AstraZeneca Hedge Fund Activity
We have seen 758 institutional investors add shares of AstraZeneca stock to their portfolio, and 820 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORGES BANK added 32,587,991 shares (+2553.6%) to their portfolio in Q2 2026, for an estimated $6,179,334,853
- JPMORGAN CHASE & CO added 19,204,823 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,641,618,537
- AMUNDI added 15,375,659 shares (+146574.4%) to their portfolio in Q1 2026, for an estimated $3,032,387,467
- RATHBONES GROUP PLC added 7,975,382 shares (+211660.9%) to their portfolio in Q2 2026, for an estimated $1,512,291,934
- ALLIANZ ASSET MANAGEMENT GMBH added 6,526,045 shares (+166650.8%) to their portfolio in Q1 2026, for an estimated $1,287,066,594
- WELLINGTON MANAGEMENT GROUP LLP added 4,786,158 shares (+20.2%) to their portfolio in Q2 2026, for an estimated $907,551,279
- MANUFACTURERS LIFE INSURANCE COMPANY, THE added 3,734,850 shares (+3404.9%) to their portfolio in Q1 2026, for an estimated $736,587,117
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AstraZeneca Government Contracts
We have seen $1,360,455 of award payments to $AZN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- STRENSIQ 80 MG/0.8 ML INJ.: $1,255,804
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
